OBJECTIVES: describe the results of therapeutic success CLIPSO's patients based on the Psoriasis Area Severity Index (PASI). METHODS: a retrospective observational cross-sectional study in patients treated from May-2018 to November-2019. To measure therapeutic success we used the delta PASI and absolute PASI and stratified the population in two groups according to begin therapy time. The first group was one who the patient began their pharmacological therapy before their enrollment in CLIPSO (prevalent) and the second group the one who started therapy in CLIPSO (incident). For the first group, we used the absolute PASI <5 (because we did not have previous information of PASI) and for second group, we used the delta PASI ≥75% and/or an absolute PASI <5. A univariate analysis and normality test (Shapiro Wilk) were performed. Association test (Spearman's correlation) to define differences between initial and final PASI and the proportion of patients who achieve therapeutic success were calculated. R Core Team statistical package (2019) was used. RESULTS: 1007 patients were evaluated (28% incidents patients with a median time of 43 days [ICR 27-56] and 72% prevalent patients with a median time of 157 days [RIC 89-290]), with a mean age of 50±15 years, the youngest was 6 and the oldest 89. The male:female ratio was 1:1. 48% were treated with non-biologic systemic therapy, 37% with biological and 14% with topical. The therapies used were Methotrexate (37.2%), Daivobet (10.7%), Adalimumab (9.4%), Ustekinumab (9%), Secukinumab (7.7%), Chemophototherapy (7.6%), Etanercept (7.3%), Acitretin (3.2 %), Ixekizumab (2.3%), Clobetasol (2.2%). 93% of the population achieved therapeutic success, with a rho between the initial and final PASI of 0.313 (p-value: 6.826e-08). CONCLUSIONS: the scope of the therapeutic success of CLIPSO's patients had a clinically relevant and statistically significant improvement.